GlassScriptPhysician profile
Lisa Berkowitz
NPI 1538425913
$4,999.59
in general payments reported to CMS, 2019-2025
23 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $911 · 2022: $788 · 2023: $1,479 · 2024: $1,253 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.64 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $775.31 | 2021-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $721.65 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $334.51 | 2021-2023 | Trintellix |
| Corium, LLC | $262.90 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $236.44 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neos Therapeutics, LP | $200.04 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Alkermes, INC. | $169.15 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $153.78 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $97.70 | 2021 | |
| Ironshore Pharmaceuticals INC. | $95.61 | 2024 | |
| Axsome Therapeutics, INC. | $58.73 | 2023 | Auvelity |
| Bausch Health US, LLC | $57.33 | 2022-2023 | Aplenzin |
| Almatica Pharma LLC | $56.97 | 2022-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $43.46 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $33.26 | 2022-2023 | Sublocade |
| Vanda Pharmaceuticals INC. | $31.00 | 2024-2025 | Fanapt |
| Bioxcel Therapeutics, INC. | $25.65 | 2024 | Igalmi |
| Pfizer INC. | $25.43 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $19.69 | 2021 | |
| Eisai INC. | $18.55 | 2021 | |
| Owp Pharmaceuticals, INC. | $18.15 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.64 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.